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Abstract 
CRISPR interference (CRISPRi) via target guide RNA (gRNA) arrays and a deactivated Cas9 
(dCas9) protein has been shown to simultaneously repress expression of multiple genomic DNA 
loci. By knocking down endogenous genes in competing pathways, CRISPRi technology can be 
utilized to re-direct metabolic flux toward target metabolite. In this study, we constructed a 
CRISPRi-mediated multiplex repression system to silence transcription of several endogenous 
genes in order to increase precursor availability in a heterologous isopentenol biosynthesis 
pathway. To identify genomic knockdown targets in competing pathways, we first designed a 
single-gRNA library with 15 individual targets, where 3 gRNA cassettes targeting gene asnA, 
prpE, gldA increased isopentenol titer by 18-24%. We then combined the 3 single-gRNA 
cassettes into two- or three- gRNA array and observed up to 98% enhancement in production by 
fine-tuning the repression level through titrating dCas9 expression. Our strategy shows that 
multiplex combinatorial knockdown of competing genes using CRISPRi can increase production 
of target metabolite, while the repression level needs to be adjusted to balance the metabolic 
network and achieve the maximum titer improvement.  
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Introduction 
Optimization of metabolic flux toward targeted biosynthesis pathway is essential for high 
productivity and yield. To re-direct carbon flux, a common approach is to reduce the production 
of excessive intermediates or byproducts by deleting genes in the competing endogenous 
pathways1,2. Since cells have evolved complex regulatory metabolic network, knocking out 
multiple endogenous pathways is often required for the enrichment of key metabolite as 
precursor of the target pathway3–7. For example, in many cases where central metabolites such as 
pyruvate and acetyl-CoA were used as a precursor for heterologous biosynthesis, host cells are 
typically engineered by knocking out genes in organic acids production or ethanol fermentative 
pathways which can substantially improve titer and productivity8–11 .  
To effectively knockout or knockdown multiple endogenous competing pathway genes, 
consecutive and combinatorial multiplex genome editing approaches have been developed and 
implemented in metabolic engineering. The multiplex automated genome engineering (MAGE) 
method facilitates simultaneous chromosomal engineering at multiple loci12. However, the lack 
of selection of edited cells via MAGE increased the capital cost of chromosomal pathway 
optimization13. As the number of target genes in the pathway increases, a number of recursive 
rounds of MAGE are required to improve editing efficiency14. In contrast to MAGE, Cas9-
mediated genome engineering using Clustered Regularly Interspaced Short Palindromic Repeats 
(CRISPR) system exerts strong selection toward edited cells by introducing a double strand 
break (DSB) in the chromosome. The successfully edited cells rely on homologous 
recombination at the DSB region using donor DNA with homology arms that matches the 
sequences flanking the DSB15–18. This approach tremendously improved genome editing 
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efficiency, while enabling scar-less genome modulation without the use of antibiotic selection19–
21.  
Assisted with CRISPR technology, simultaneously editing of multiple genome loci was achieved 
in Saccharomyces species22 and some mammalian cell lines23. However, for many industrial 
prokaryotic hosts, it is still difficult to modulate multiple places in the chromosome at the same 
time due to the low homologous recombination efficiency. In E. coli, while the editing efficiency 
of two genes is around 80%, the efficiency drops to 20% when targeting three genes 
simultaneously24. In some cases, the modified cells possess a phenotypic advantage; therefore 
screening assays can be used for enrichment of successful edits, resulting in 70% efficiency of 
three gene targets25. However, in most of the cases where no obvious phenotypic change is 
associated with genome editing, it is difficult to design enrichment assays to obtain high editing 
efficiency of multiple genes.    
To bypass the low chromosomal pasting rate in many prokaryotes, CRISPR interference 
(CRISPRi) via a deactivated Cas9 (dCas9) protein has been utilized to repress expression of 
multiple genomic loci. Bound with target guide RNA (gRNA), dCas9 protein lacks catalytic 
activity but still retains strong specific DNA binding function, which can sufficiently suppress 
gene transcription26,27. As a multiplex genome engineering tool, CRISPRi technology has been 
utilized to optimize heterologous biosynthesis by knocking down both endogenous competing 
pathways and exogenous genes on production plasmids28–32. In E. coli terpenoid biosynthesis, for 
example, production of bisabolene and lycopene were enhanced by repressing plasmid-borne 
MVA pathway genes while production of isoprene increased by repressing endogenous gene 
ispA33. Similarly, in anthocyanin biosynthesis, repression of a single endogenous gene 
deregulated the competing methionine biosynthetic pathway and improved precursor availability 
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30. Recently, simultaneous suppression of three genes (gabD, ybgC and tesB) enhanced 1,4-
butanediol biosynthesis, while repression of four genes (pta, frdA, ldhA, and adhE) increased n-
butanol productivity and yield32. Not only in E. coli, in other industrial hosts, CRISPRi 
technology has also been widely studied. In C. glutamicum, repression for individual gene pgi, 
pck and pyk resulted in titer enhancement for L-lysine and L-glutamate production 29. In 
cyanobacteria, simultaneous knockdown of 4 genes led to repression of carbon storage 
compounds formation during nitrogen starvation31.  
In this study, we applied CRISPRi-mediated repression of endogenous competing pathways for 
production of an isoprenoid-derived C5 alcohol, isopentenol. Isopentenol (or 3-methyl-3-buten-
1-ol) is a biofuel blend-in and precursor for many industrial chemicals such as prenol, isoprene 
and isoamyl alcohol esters34,35. Although considerable research has been devoted to engineer the 
isopentenol biosynthesis pathway36–38, little attention has been paid to vary the genetic 
background and re-route metabolic intermediates. To achieve sufficient isopentenol production, 
we employed a previous engineered, 2-plasmid biosynthesis platform by overexpressing genes 
encoding the MVA pathway and nudB to convert isopentenyl diphosphate (IPP) to isopentenol38. 
We targeted 21 individual endogenous genes in competing pathways to divert carbon flux toward 
IPP precursor synthesis. We then selected three of those targets with increased isopentenol titer 
to further perform combinatorial knockdown. We observed up to 98% enhancement in 
production with multiplex combinatorial repression comparing to base strain. To our knowledge, 
this is the first report that uses CRISPRi to systematically identify target genes in isopentenol 
biosynthesis. This work provides an alternative approach for genome-wide discovery of 
knockdown/knockout loci for metabolic engineering of the isoprenoids biosynthesis. 
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Results 
Initial design of CRISPRi-mediated repression system for isopentenol production 
To control the repression level and timing of endogenous chromosomal genes, we constructed a 
tetracycline-inducible dCas9 system using customized CRISPR gRNA (crRNA) array (Figure 1). 
The use of inducible system enabled tunable repression of genes in competing pathways which 
could include essential genes, expanding the number of chromosomal loci we can target. In 
addition, since permanent gene knockout and knockdown may reduce growth rate, the use of 
inducible CRISPRi also allowed us to control the timing of repression of chromosomal genes. 
Hence, before induction of CRISPRi, the metabolic flux can be distributed toward reproduction, 
energy generation and other metabolism necessary for rapid cell growth; after induction of dCas9, 
the metabolic flux can be diverted toward the target isopentenol biosynthesis pathway, which 
largely reduced the negative impact of gene knockdown on cell growth (Figure 1B). In addition, 
the CRISPR array allows multi-gene targeting with a single transcript. Compared to the design of 
Figure 1 Schematic description of the isoprenoid production system using CRISPRi-mediated 
repression. (A) The isoprenoid pathway consists of two plasmids, converting glucose to 3-
methyl-3-butenol. The dCas9 protein is controlled by a tetracycline-inducible promoter, and the 
gRNA array is controlled by a strong constitutive promoter J23100. (B) Before the induction of 
dCas9 protein, the cell may distribute its cellular resources and metabolic flux for growth, 
secondary metabolite production, energy generation and so on. After the induction of dCas9, the 
cell can re-direct metabolic flux toward our target production. 
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synthetic gRNA, CRISPR array eliminated the utility of promoter and terminator for each single 
gRNA, which shortened the sequence length when targeting multiple loci. 
To obtain sufficient isopentenol production, we employed a previously engineered 2-plasmid 
isopentenol biosynthesis platform (Figure 1A). Plasmid 1 contains 5 genes expressing the 
heterologous MVA pathway under control of trc promoter (Ptrc): atoB, HMGS, HMGR, MK, 
PMK, which converts central metabolite acetyl-CoA to mevalonate diphosphate; Plasmid 2 
contains two genes under lacUV5 promoter (PlacUV5): nudB and PMD, converting mevalonate 
diphosphate to isopentenol. The isopentenol production pathway will be induced after the 
induction of CRISPRi-mediated repression system, so that endogenous genes in the competing 
pathways can be fully down-regulated prior to the target pathway biosynthesis. 
To establish an initial design of CRISPRi-mediated repression system, we constructed a plasmid 
with dCas9 and gRNA under a natural constitutive promoter (Pdcas9-Marraffini) from S. pyogenes
27. 
To determine the repression efficiency of a gRNA targeting different DNA strands and different 
locations on a gene, we used a chromosomal RFP as a reporter, and designed nine gRNA 
Figure 2 RFP repression efficiency with different gRNAs. (A) Top: plasmid design of the 
constitutively expressed dCas9 and crRNA. dCas9 was controlled by its natural promoter Pdcas9, crRNA 
was placed downstream of dCas9, also expressed from promoter Pdcas9. Bottom: different gRNAs 
targeting different DNA strands and location of RFP. P: targeting promoter region, NT: targeting non-
template strand, T: targeting template strand. (B) Repression efficiency of different gRNA measured 
by RFP fluorescence per cell. The nontarget gRNA is a sequence that doesn’t target E. coli genome. 
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sequences to target the RFP. This includes three gRNAs targeting promoter regions (P1, P2, P3), 
three gRNAs targeting non-template coding strand (NT1, NT2, NT3) and three gRNAs targeting 
the template coding strand (T1, T2, T3) (Figure 2). We observed higher repression efficiency 
targeting the non-template regions for the open reading frame. While for promoter region, 
targeting either strand renders similar repression level. Among all those gRNAs, we obtained 
115-fold, 63-fold, and 58-fold from gRNA NT1, NT2, NT3, respectively, suggesting that 
targeting the beginning of transcript leads to higher repression, which is consistent to previous 
findings26. In addition, we obtained 126-fold and 128-fold repression from plasmid bearing 
gRNA P1 and P3, but only 24-fold repression from gRNA P2, indicating that targeting the region 
from -10 to -35 of promoter region has higher efficiency than targeting the region upstream of -
10 of the promoter. 
 
Optimization of a tunable CRISPRi system 
In the next step, we aimed to construct a tunable CRISPR-dCas9 system to conditionally 
knockdown endogenous genes based on previous plasmid architecture. We selected the 
tetracycline-inducible promoter (Ptet) to drive the dCas9-gRNA repression system due to its 
relatively tight regulatory capability (Figure 3). We built CRISPR-dCas9 plasmid variants using 
NT1 gRNA sequence since it reflected high targeting efficiency (Figure 2B). And we continued 
to use the chromosomal RFP as a reporter to measure repression level of the CRISPRi variants. 
Both wild type Ptet_wt promoter
39 and an engineered low-leakage Ptet_eng promoter variant
40 were 
employed to drive dCas9 and gRNA expression, resulting in variant strain C1 and C2. However, 
neither cassette succeeded in reducing RFP gene expression upon increasing concentration of 
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anhydrous tetracycline (aTc). The Ptet_wt promoter in C1 turns out to be extremely leaky that even 
without adding any aTc inducer, the system repressed RFP fluorescence by 7-fold.  
On the contrary, the Ptet_eng promoter in C2 was not leaky but failed to repress RFP expression at 
any inducer concentration. We suspected that this malfunction of C1 and C2 is due to the lack of 
gRNA level, as insufficient gRNA expression can cause complex non-linear repression behavior 
or no repression at all24,33. Therefore, we inserted a strong constitutive promoter PJ23119 upstream 
of the gRNA sequence, generating C3 and C4 from C1 and C2. Consequently, the leakiness of 
C3 system has been substantially reduced. Also, C4 system efficiently decreased RFP 
fluorescence at varying inducer concentrations while maintained its tight regulation.  
Figure 3 Construction and characterization of CRISPR-dCas9 repression cassettes. (A) Schematics of 
CRISPR-dCas9 variants with different promoters driven dCas9, crRNA and tetR gene. Red color is 
used in promoter names to emphasize the difference in each system. (B) Characterization of repression 
efficiency of different cassettes with varying anhydrous tetracycline inducer concentrations. (C) Time-
course repression response of different cassettes with varying inducer concentrations. 
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To reduce the metabolic burden of overexpressing dCas9 protein41, we replaced the replication 
origin of plasmids in C3 and C4 from a medium copy (p15A) to a low copy origin (SC101). The 
resultant strains C5 and C6 both remains their high repression efficiency, while C5 is still leakier 
than C6. Without adding any inducer, the RFP fluorescence for C5 and C6 is 42% and 22% less 
than the control strain harboring non-targeting gRNA respectively (Figure 3B).  
To investigate the expression kinetics for genes targeted by CRISPR-dCas9 system, we 
measured the RFP fluorescence change over time among different plasmid variants. Except for 
C1 and C2, the RFP fluorescence in other strains can be reduced to >50% after 6 hours, >85% 
after 9 hours, and >90% after 20 hours of its wild type with 5 nM aTc (Figure 3C). Considering 
RFP is engineered with high protein stability and long half-life, we anticipated that when 
applying this repression system to regulate endogenous E. coli genes, their protein level may 
decrease faster than our current RFP data due to higher degradation rate. Based on this analysis, 
we chose to induce expression of the isopentenol pathway 6 hours after activating the CRISPRi-
mediated repression system. 
 
CRISPRi negatively affects gene expression in the same operon 
Since dCas9 protein represses gene expression at a transcription level, we explored whether 
targeting one gene using CRISPR-gRNA in an operon will affect the expression level of the rest 
of genes. We constructed a bicistronic operon on plasmid with RFP as an upstream and GFP as a 
downstream gene. Both genes are regulated by a constitutive synthetic promoter PJ23100 (Figure 
4).  
11 
 
We designed three gRNAs targeting the promoter (P), the beginning of RFP coding sequence 
(RFPNT) and the beginning of GFP coding sequence (GFPNT). We used plasmids (JBEI-18655, 
JBEI-18648) from strain C5 and C6 to construct the repression systems bearing those gRNAs 
and transformed both the repression plasmids and the RFP-GFP operon plasmid (JBEI-18698) 
into the cells, creating strains C5P, C5RFPNT, C5GFPNT, C6P, C6RFPNT, C6GFPNT. Since 
dCas9 inhibits transcription of mRNA, we hypothesized that by targeting the upstream transcript, 
the downstream transcript will no longer be expressed. As we expected, for both C5- and C6-
based systems, targeting the promoter region and RFP coding sequence led to over 95% 
reduction in both RFP and GFP fluorescence while targeting GFP coding sequence led to over 97% 
decrease in GFP fluorescence with respect to the wild type controls. However, to our surprise, 
we observed 79% and 86% RFP fluorescence reduction respectively in C5GFPNT and 
Figure 4 Repression properties of CRISPR-dCas9 system for genes in an operon. Top: Schematics 
indicating the location of target gRNA in the operon. Middle: RFP fluorescence in response to different 
gRNA. Bottom: GFP fluorescence in response to different gRNA. 
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C6GFPNT by only targeting the downstream GFP coding sequence. We postulated that targeting 
the downstream mRNA will shorten the entire transcript and may also decrease the mRNA 
stability, which may result in reduced expression. However, to draw any conclusion, RNA level 
should be quantified for both RFP and GFP with the three gRNAs, which could be an interesting 
scope to explore in the future.  
When varying the inducer concentration for our CRISPRi system, we observed a sharp decrease 
(up to 28-fold) in the targeted gene expression between 0 and 5 nM aTc; then, a relatively low 
repression (up to 8-fold) between 5 nM and 10 nM aTc; and limited change in signal (up to 1.5-
fold) with higher inducer concentration (Figure 2 and 3). This observation indicates that our 
system exhibits a step-change behavior. Therefore, we next chose 0, 5 and 10 nM inducer 
concentration to control the repression strength in the genome-wide knockdown experiments.   
 
Efficient multiplex repression of CRISPRi system reduced acetate production  
To test whether our repression system can efficiently down-regulate multiple endogenous genes 
simultaneously, we constructed CRISPR array carrying multiple gRNAs using both C5- and C6-
based cassette architectures (Figure 5B). The gRNA array is composed of spacer-repeat blocks 
that are processed into mature targeting gRNAs by the wildly conserved endogenous RNase III42. 
In E. coli, enzymes encoded by poxB converts pyruvate to acetate and genes pta and ackA 
encode enzymes converting acetyl-CoA to acetate (Figure 5A). Previous studies have reported 
that the deletion of only poxB or the deletion of only ackA-pta operon does not reduce the acetate 
production in wild type E. coli cells8. Taking advantage of this knowledge, we hypothesized that 
if our repression cassette functions efficiently for multi-gene repression, our crRNA array 
carrying three gRNAs targeting poxB, ackA and pta genes can reduce acetate formation, while a 
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strain harboring single-gRNA dCas9 plasmid will still produce acetate to the level comparable to 
that of wild type cells.  
We used a strain with pta, poxB and ackA knockouts as a positive control, and E. coli wild type 
strain as a negative control, both strains harbored an empty plasmid vector. After growing strains 
for overnight, we inoculated the cells in EZ rich medium with 1% glucose, while inducing the 
dCas9 protein with 10 nM aTc. After 24 hours, cells were harvested, and the acetate levels were 
measured by HPLC. As expected, the acetate level with triple-gRNA repression plasmid 
decreased by 4.8-fold for strain C5-poxB-ackA-pta and 3.4-fold for strain C6-poxB-ackA-pta 
Figure 5 Implementation of multi-gRNA CRISPR-dCas9 system for inhibition of acetic acid formation. 
(A) schematic description of the acetate production pathway in E. coli. (B) Schematic description of 
repression cassettes based on pC5 and pC6 plasmids bearing three-gRNA array targeting gene poxB, 
ackA, pta in the chromosome. (C) Acetate formation between wild type E. coli, knockout strain and 
strains bearing different gRNA arrays. 
 
14 
 
(Figure 5C). In contrast, slightly elevated acetate levels were observed with strains harboring 
single-gRNA targeting pta or ackA gene (C5-ackA, C5-pta, C6-ackA, C6-pta), which is 
consistent with the findings by Goh et al, indicating that acetate may be produced via an 
alternative pathway11. Comparing to the knockout strain, strain C5-poxB-ackA-pta still generated 
2.2-fold more acetate, which may be resulted by the delay in repression due to induction kinetics 
or the incomplete repression of knockdown system. These data demonstrated that our CRISPRi 
system can efficiently down-regulate multiple endogenous genes at the same time. Since the 
strain C5-poxB-ackA-pta produced less acetate than the C6-poxB-ackA-pta strain, in the next 
step, we selected C5-based system to perform knockdown experiment to re-directing metabolic 
flux for isopentenol production.  
 
Redirecting metabolic flux for isopentenol production 
To identify repression targets in competing pathways for isopentenol production, we selected 15 
genes based on previously selected knockout targets for lycopene or carotenoid production using 
MEP pathway. Since both MEP and MVA pathway shares the same precursor IPP, we 
hypothesize that the knockout gene targets identified for MEP pathway to improve IPP and 
DMAPP accumulation may also apply for isopentenol production using MVA pathway. We also 
selected 3 additional genes gltA, accA and ispA, which catalyze the key steps in TCA cycle, fatty 
acids synthesis, and FPP production using IPP as precursor metabolite, respectively (Figure 6A). 
All together, we constructed 18 single-gRNA based on C5 version of plasmid and co-
transformed them with the KG1R10 isopentenol production strain
38. Meanwhile, plasmid from 
C5-poxB-ackA-pta was also co-transformed into strain KG1R10 expecting isopentenol titer 
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improvement in this strain by decreasing flux to acetate. We also introduced an empty vector 
plasmid into cells harboring production plasmids as control (base strain).  
 
Upon inoculation, CRISPRi was activated with 10 nM aTc, and after 6 hours, the production 
pathway was induced by adding IPTG for isopentenol biosynthesis. Samples were taken for 
isopentenol production measurement at 24, 48 and 72 hours. We found that strain harboring the 
triple-gRNA plasmid targeting the acetate formation pathway improved isopentenol production 
by 37%. Strains C5-asnA, C5-gldA, C5-prpE bearing single-gRNA also improved isopentenol 
production by 18-24%, where genes asnA, gldA, prpE are involved in asparagine production, 
glycerol utilization, and propionyl-CoA synthesis, respectively (Figure 6B). We observed strong 
Figure 6 Re-directing metabolic flux toward isopentenol production using CRISPR-dCas9 repression 
system. (A) Pathway map of gene knockdown target. Red colored genes are the knockdown targets, green 
colored genes are overexpressed on two plasmids. (B) Isopentenol production (top) and growth (bottom) 
with dCas9-gRNA plasmids targeting different genes.  
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correlation between biomass accumulation and isopentenol production (R2=0.78), which 
indicated that down-regulation of some genes slowed down the cell growth, thus reduced the 
final titer of production. 
In the next step, we combined the three gRNAs targeting asnA, gldA, prpE into two- and three- 
gRNA arrays and co-transformed them into KG1R10, creating strain C5-asnA-gldA, C5-asnA-
prpE, C5-gldA-prpE, and C5-asnA-gldA-prpE (Figure 7). We varied the magnitude of repression 
Figure 7 Combinatorial multiplex repression using CRISPR-dCas9 system for isopentenol production. 
Isopentenol production (top) and cell density data (bottom) after 24 and 48 hours. On the x-axis, top row 
shows anhydrous tetracycline concentration, bottom row shows the targeted multiple genes using 
CRISPR-dCas9 system. 
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by adding inducer at 0, 5, 10 nM. As previously shown, the uninduced CRISPRi system is 
responsible for 42% RFP fluorescence reduction with respect to its wild type control, due to the 
leaky expression of Ptet_wt (Figure 3B). We speculated that repression of endogenous genes could 
occur at lower rate in the absence of aTc. We observed 98% improvement in isopentenol 
production from C5-asnA-gldA-prpE at 0 nM aTc compared to the base strain, suggesting that 
relatively weak simultaneous repression of three genes asnA, gldA and prpE, can result in 
considerable improvement in isopentenol production. For the two-gRNA arrays, we observed 90% 
and 69% improvement, respectively in strain C5-asnA-prpE and C5-gldA-prpE with 5 nM aTc, 
which indicates that a relatively high level of repression is required when the combination of two 
genes asnA, prpE or gldA, prpE are targeted. These results imply that while individual gene 
knockdown may have low impact in diverting metabolic flux, selective combinatorial multiplex 
repression of those genes could lead to substantial improvement in production. In addition, since 
the improvement of isopentenol production was obtained with different repression levels, we 
concluded that knockdown of genes in competing pathways may need to be tuned to balance the 
metabolic flux, so that the repressed genes can still be expressed to some extent for maintaining 
normal cellular function, while resources can be re-directed toward target metabolite to increase 
precursor accumulation. 
 
Discussion 
In this work, we investigated the impact of CRISPRi on gene expression in polycistronic operon. 
We observed that by targeting the middle of an mRNA, not only the downstream transcription 
can be dramatically inhibited; the upstream gene expression can also be reduced to some extent 
possibly due to mRNA stability decrease (Figure 4). In E. coli, an estimation of 40.53% of genes 
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present in pairs and clusters43. Fortunately, most of the clustered genes are functionally related; 
therefore, when targeting one gene in an operon using CRISPRi system, it may lead to a 
coordinated effect by repressing other functionally-related genes in the same operon44,45. 
However, in the cases where polycistronic genes exhibit functional dissimilarities, the use of 
CRISPRi to repress genes in operons needs to be reevaluated and reconsidered. 
In constructing the inducible CRISPRi system, we found that the uninduced condition accounts 
for 42% RFP fluorescence reduction of its wild type control due to the leaky expression of Ptet_wt 
promoter. Later in our production experiment, this uninduced Ptet_wt also result in 98% 
improvement in isopentenol titer. These observations imply that CRISPR system can efficiently 
target genomic DNA with even a residual promoter activity, which is consistent with previous 
research by Garst and co-workers46. In their study, the uninduced Cas9 was reported to achieve 
80% genome editing due to leaky pBAD expression, while the induced Cas9 achieved 90% 
efficiency46. Additionally, considering RFP is optimized with enhanced stability, its half-life is 
about 26 hours47, while most of E. coli native proteins have half-lives about 2 to a few hours48, 
the reduction in protein expression of E. coli native genes by uninduced CRISPRi during 
isopentenol production experiment may be greater than 42%.    
The use of inducible promoter to control the expression of dCas9 protein enables tunable 
knockdown of target genes. By changing the inducer concentration, we substantially improved 
isopentenol production at varying levels of repression when targeting different combinations of 
genes. These results suggest that the repression strength needs to be adjusted to balance the flux 
toward making desired product and maintaining normal cellular functions. Hence, a tunable 
knockdown system can be a powerful tool in identifying the “sweet spot” in re-directing 
metabolic flux for production optimization. Our finding is also in agreement with previous study 
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using synthetic small RNA (sRNA) to construct fine-tuned knockdown system, where the 
authors discovered that relatively low expression of sRNAs is needed for putrescine 
overproduction and relatively high expression of sRNAs is needed for L-proline production49. 
As an emerging tool for modulating endogenous gene expression, CRISPRi has been used in 
various biosynthesis pathways in E. coli including production of anthocyanin, n-butanol, 1,4-
butanediol, isoprene, lycopene and bisabolene28,30,32. All without exception, the selected knock-
down genes using CRISPRi system in those biosynthesis pathways have been previously known 
deletion targets. In contrast, we identified novel knock-down gene targets, which could 
potentially be used for a variety of monoterpenes and sesquiterpene biosynthesis since the 
terpenoid pathways share universal building block (IPP). We found three genes asnA, gldA, and 
prpE responsible for L-aspargine formation, glycerol utilization and propanyol-CoA synthesis, 
respectively, can lead to higher isopentenol production. While targeting those individual genes 
only generated moderate titer improvement, a simultaneous down-regulation of these three genes 
rendered almost 2-fold increase in production. As a result, we provided another example that 
CRISPRi can be a potential high-throughput screening tool to determine endogenous targets. 
Those identified targets can be further tested for chromosomal knockout or knockdown to 
generate a more stable genomic background.  
  
Conclusion 
In the present work, we developed a combinatorial multiplex repression system using CRISPRi 
to conditionally down-regulate endogenous genes in competing pathways for isopentenol 
production. We designed plasmid harboring dCas9 and gRNA array with SC101 replication 
origin and gentamicin resistance, which is easily compatible with commonly used production 
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vectors for a variety of chemical biosynthesis. By targeting three genes poxB, ackA and pta in 
acetate production pathway, we obtained 4.8-fold decrease in acetate with respect to control 
strain, which demonstrated that our CRISPRi system can effectively repress multiple genes 
simultaneously. Additionally, we employed CRISPRi to divert metabolic flux toward isopentenol 
production by repressing genes in competing pathways. We first created a single-gRNA 
CRISPRi library targeting 15 individual chromosomal loci in competing pathways. We then 
selected the single-gRNA with improved isopentenol production and constructed double and 
triple gRNA array in combination. The resultant gRNA arrays generated up to 98% increase in 
isopentenol titer, which suggested that CRISPRi can be used as an alternative approach to 
identify novel knockdown targets for balancing metabolic pathways. 
 
Materials and Methods 
Construction of plasmids 
To construct constitutively expressed dCas9 cassette targeting different DNA strands and 
locations of RFP reporter gene in the chromosome (strain JBEI-14034), golden gate assembly 
method was employed and the plasmid pdCas9-Marraffini was used as base plasmid27. pdCas9-
Marraffini used a constitutive promoter to control dCas9 protein and crRNA, with ColE1 origin 
and CmR marker on the vector. The resultant 9 plasmids (JBEI-18664, JBEI-18662, JBEI-18661, 
JBEI-18658, JBEI-18657, JBEI-18665, JBEI-18679, JBEI-18676, JBEI-18674), targeting 
different DNA strands and locations were transformed into strain JBEI-14034 to test their 
repression efficiencies.  
To construct tetracycline inducible dCas9 system, Gibson assembly was employed using JBEI-
18679 as base plasmid, which targets the beginning of non-template region of RFP. 6 different 
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cassettes were constructed (JBEI-18647, JBEI-18652, JBEI-18653, JBEI-18654, JBEI-18655, 
JBEI-18648), whose repression efficiency was tested by measuring RFP fluorescence reduction. 
Two Ptet promoters were tested, Ptet_wt is the wild type promoter from JBEI parts registry
39, 
Ptet_eng is the engineered promoter from iGem parts registry
50. JBEI-18647, JBEI-18653, JBEI-
18655 contains wild type Ptet promoter and the rest contains engineered Tet promoter. For each 
tetracycline-inducible dCas9 system, we also built its corresponding non-targeting plasmid 
(JBEI-18670, JBEI-18669, JBEI-18667, JBEI-18692, JBEI-18689, JBEI-18697).  
To construct plasmids targeting RFP and GFP genes in the same operon, JBEI-18655 was used 
to generate JBEI-18650, JBEI-18651 and JBEI-18649 targeting the promoter of RFP, the RFP 
coding sequence and the GFP coding sequence respectively. While JBEI-18648 was used to 
generate JBEI-18671, JBEI-18672 and JBEI-18673 targeting the promoter of RFP, the RFP 
coding sequence and the GFP coding sequence respectively. JBEI-18655 and JBEI-18648 were 
also used to generate plasmids to target poxB, ackA and pta genes. For isopentenol production, 
only JBEI-18655 was used to generate plasmids to target the 18 newly identified genes 
individually and in combination. 
Strains, medium and growth 
For fluorescence test, E. coli DH1 strain harboring two plasmids, pJ23100-RFP-GFP and the 
corresponding dCas9-gRNA plasmid were cultured in LB. Cell cultures were first cultured in 
tubes overnight then diluted to fresh LB with anhydrous tetracycline in 96-well deep-well plate 
to OD about 0.02. The Tecan plate reader automatically read OD and fluorescence in every 20 
minutes for 20 hours.  
For production test, E. coli DH1 was co-transformed with two isopentenol production plasmids 
and a repression plasmid with dCas9 gene and gRNA targeting chromosomal genes. Culture was 
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first grown in LB for overnight, and then transferred into 5 mL EZ rich medium with 1% glucose 
and 10 nM anhydrous tetracycline (aTc) in culture tube at 37°C. After 6 hours, when OD of cells 
reached 1,500 μM isopropyl β-D-1-thiogalactopyranoside (IPTG) was added to induce the cells, 
and then cells were grown at 30°C. At 24, 48, and 76-hour post-induction, 250 µL culture were 
sampled and diluted into 250 µL of ethyl acetate spiked with n-butanol as an internal standard.  
Analysis and detection of isopentenol 
For isopentenol quantification, 250 μL of cell culture was combined with 250 μL of ethyl acetate 
containing 1-butanol (32 mg/L) as an internal standard. This mixture of ethyl acetate and cell 
culture was vigorously shaken for 15 min and subsequently centrifuged at 15,000g for 2 min to 
separate ethyl acetate from the aqueous phase. 100 μL of the ethyl acetate layer was diluted 5-
fold, and 1 μL was analyzed by Agilent GCMS equipped with Cyclosil-B column (Agilent, USA) 
or Thermo GCFID equipped with DB-WAX column (Agilent, USA) for quantitation of 
isopentenol. 
The method used by the GCMS has the following settings: inlet at 250°C, 1 mL/min constant 
flow, sample 1 µL from each vial. The oven was started at 45°C for 2 min, first ramped to 150°C 
at 12°C/min, then ramped to 250°C at 40°C/min, and held at 250°C for 1 min. The method used 
by GCFID has the following settings: The oven was started at 40°C, first ramped to 100°C at 
15°C/min, then ramped to 230°C at 40°C/min, and held at 230°C for 3 min. 
Analysis and detection of RFP and GFP fluorescence 
For measurements taken by plate reader, RFP fluorescence was measured on an Infinite F200 
PRO (Tecan, Männedorf, Switzerland) for 20 hours, with excitation at 575±10 nm and emission 
at 620±10 nm. All fluorescence values were normalized to cell density by measuring optical 
density at 600 nm (OD600). For measurements using flow cytometer, 10 μL samples were added 
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to 200 μL Phosphate Buffered Saline (PBS) supplemented with 2 mg/mL kanamycin for halting 
growth. Single-cell RFP and GFP fluorescence from at least 50,000 cells were recorded by a BD 
C6 Accuri flow cytometer (BD Bioscience, USA). GFP fluorescence was measured with FL1 
detector and RFP fluorescence was measured with FL4 detector. The average expression level 
was determined by taking the average of the fluorescence distribution and subtracting the 
average auto-fluorescence of wild type E. coli strain. 
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Table 1. Plasmids and strains. Strains with JBEI plasmid are available at JBEI public registry 
(https://public-registry.jbei.org) and searchable using JPUB number. 
Plasmids  JPUB_number Description Reference 
JBEI-18646 JPUB_011251 PdCas9-Marraffini, p15A, CmR 27 
JBEI-18664 JPUB_011253 PConst-dCas9-T1 This study 
JBEI-18662 JPUB_011255 PConst-dCas9-T2 This study 
JBEI-18661 JPUB_011257 PConst-dCas9-T3 This study 
JBEI-18658 JPUB_011259 PConst-dCas9-P1 This study 
JBEI-18657 JPUB_011261 PConst-dCas9-P2 This study 
JBEI-18665 JPUB_011263 PConst-dCas9-P3 This study 
JBEI-18679 JPUB_011265 PConst-dCas9-NT1 This study 
JBEI-18676 JPUB_011267 PConst-dCas9-NT2 This study 
JBEI-18674 JPUB_011269 PConst-dCas9-NT3 This study 
JBEI-18647 JPUB_011271 PTet-wt-dCas9-NT1, p15A, CmR This study 
JBEI-18652 JPUB_011273 PTet-eng-dCas9-NT1, p15A, CmR This study 
JBEI-18653 JPUB_011275 PTet-wt-dCas9-PJ23119-NT1, p15A, CmR This study 
JBEI-18654 JPUB_011277 PTet-eng-dCas9-PJ23119-NT1, p15A, CmR This study 
JBEI-18655 JPUB_011279 PTet-wt-dCas9-PJ23119-NT1, pSC101, GmR This study 
JBEI-18648 JPUB_011281 PTet-eng-dCas9-PJ23119-NT1, pSC101, GmR This study 
JBEI-18670 JPUB_011283 PTet-wt-dCas9-nontarget, p15A, CmR This study 
JBEI-18669 JPUB_011285 PTet-eng-dCas9-nontarget, p15A, CmR This study 
JBEI-18667 JPUB_011287 JBEI-14034, PTet-wt-dCas9-PJ23119-nontarget, p15A, CmR This study 
JBEI-18692 JPUB_011289 JBEI-14034, PTet-eng-dCas9-PJ23119-nontarget, p15A, CmR This study 
JBEI-18689 JPUB_011291 JBEI-14034, PTet-wt-dCas9-PJ23119-nontarget, pSC101, GmR This study 
JBEI-18697 JPUB_011293 JBEI-14034, PTet-eng-dCas9-PJ23119-nontarget, pSC101, GmR This study 
JBEI-18706 JPUB_011369 JBEI-14034, PTet-wt-dCas9-PJ23119-nontarget, pSC101, KanR This study 
JBEI-18707 JPUB_011371 JBEI-14034, PTet-eng-dCas9-PJ23119-nontarget, pSC101, KanR This study 
JBEI-18698 JPUB_011367 PJ23100-RFP-GFP, p15A, KanR This study 
JBEI-18650 JPUB_011295 PTet-wt-dCas9-PJ23119-P1, pSC101, GmR This study 
JBEI-18651 JPUB_011297 PTet-wt-dCas9-PJ23119-RFPNT, pSC101, GmR This study 
JBEI-18649 JPUB_011299 PTet-wt-dCas9-PJ23119-GFPNT, pSC101, GmR This study 
JBEI-18671 JPUB_011301 PTet-eng-dCas9-PJ23119--P1, pSC101, GmR This study 
JBEI-18672 JPUB_011303 PTet-eng-dCas9-PJ23119-RFPNT, pSC101, GmR This study 
JBEI-18673 JPUB_011305 PTet-eng-dCas9-PJ23119-GFPNT, pSC101, GmR This study 
JBEI-18684 JPUB_011307 DH1, PTet-wt-dCas9-PJ23119-poxB, pSC101, KanR This study 
JBEI-18681 JPUB_011309 DH1, PTet-wt-dCas9-PJ23119-ackA, pSC101, KanR This study 
JBEI-18663 JPUB_011311 DH1, PTet-wt-dCas9-PJ23119-pta, pSC101, KanR This study 
JBEI-18686 JPUB_011313 DH1, PTet-wt-dCas9-PJ23119-poxB-ackA-pta, pSC101, KanR This study 
JBEI-18704 JPUB_011315 DH1, PTet-eng-dCas9-PJ23119-poxB, pSC101, KanR This study 
JBEI-18705 JPUB_011317 DH1, PTet-eng-dCas9-PJ23119-ackA, pSC101, KanR This study 
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JBEI-18702 JPUB_011319 DH1, PTet-eng-dCas9-PJ23119-pta, pSC101, KanR This study 
JBEI-18703 JPUB_011321 DH1, PTet-eng-dCas9-PJ23119-poxB-ackA-pta, pSC101, KanR This study 
JBEI-3279 JPUB_000262 pBbS0k 37 
JBEI-18687 JPUB_011323 PTet-wt-dCas9-PJ23119-arcC, pSC101, KanR This study 
JBEI-18660 JPUB_011325 PTet-wt-dCas9-PJ23119-yahI, pSC101, KanR This study 
JBEI-18700 JPUB_011327 PTet-wt-dCas9-PJ23119-yqeA, pSC101, KanR This study 
JBEI-18690 JPUB_011329 PTet-wt-dCas9-PJ23119-gltA, pSC101, KanR This study 
JBEI-18683 JPUB_011331 PTet-wt-dCas9-PJ23119-accA, pSC101, KanR This study 
JBEI-18668 JPUB_011333 PTet-wt-dCas9-PJ23119-eutD, pSC101, KanR This study 
JBEI-18675 JPUB_011335 PTet-wt-dCas9-PJ23119-deoB, pSC101, KanR This study 
JBEI-18678 JPUB_011337 PTet-wt-dCas9-PJ23119-ppc, pSC101, KanR This study 
JBEI-18701 JPUB_011339 PTet-wt-dCas9-PJ23119-yhfW, pSC101, KanR This study 
JBEI-18659 JPUB_011341 PTet-wt-dCas9-PJ23119-thrC, pSC101, KanR This study 
JBEI-18693 JPUB_011343 PTet-wt-dCas9-PJ23119-ispA, pSC101, KanR This study 
JBEI-18680 JPUB_011345 PTet-wt-dCas9-PJ23119-mdh, pSC101, KanR This study 
JBEI-18685 JPUB_011347 PTet-wt-dCas9-PJ23119-asnA, pSC101, KanR This study 
JBEI-18677 JPUB_011349 PTet-wt-dCas9-PJ23119-prpE, pSC101, KanR This study 
JBEI-18666 JPUB_011351 PTet-wt-dCas9-PJ23119-gldA, pSC101, KanR This study 
JBEI-18682 JPUB_011353 PTet-wt-dCas9-PJ23119-mqo, pSC101, KanR This study 
JBEI-18695 JPUB_011355 PTet-wt-dCas9-PJ23119-maeB, pSC101, KanR This study 
JBEI-18694 JPUB_011357 PTet-wt-dCas9-PJ23119-dacA, pSC101, KanR This study 
JBEI-18691 JPUB_011359 PTet-wt-dCas9-PJ23119-asnA-gldA, pSC101, KanR This study 
JBEI-18696 JPUB_011361 PTet-wt-dCas9-PJ23119-asnA-prpE, pSC101, KanR This study 
JBEI-18656 JPUB_011363 PTet-wt-dCas9-PJ23119-gldA-prpE, pSC101, KanR This study 
JBEI-18688 JPUB_011365 PTet-wt-dCas9-PJ23119-asnA-gldA-prpE, pSC101, KanR This study 
Strains Description Reference 
JBEI-14034 (JPUB_011194) MG1655 trxA::P3-BCD2-RFP-FRT-Km This study 
C0-nontarget JBEI-14034 + JBEI-18646 This study 
T1 JBEI-14034 + JBEI-18664 This study 
T2 JBEI-14034 + JBEI-18662 This study 
T3 JBEI-14034 + JBEI-18661 This study 
P1 JBEI-14034 + JBEI-18658 This study 
P2 JBEI-14034 + JBEI-18657 This study 
P3 JBEI-14034 + JBEI-18665 This study 
NT1 JBEI-14034 + JBEI-18679 This study 
NT2 JBEI-14034 + JBEI-18676 This study 
NT3 JBEI-14034 + JBEI-18674 This study 
C1 JBEI-14034 + JBEI-18647 This study 
C2 JBEI-14034 + JBEI-18652 This study 
C3 JBEI-14034 + JBEI-18653 This study 
C4 JBEI-14034 + JBEI-18654 This study 
C5 JBEI-14034 + JBEI-18655 This study 
C6 JBEI-14034 + JBEI-18648 This study 
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C1-nontarget JBEI-14034 + JBEI-18670 This study 
C2-nontarget JBEI-14034 + JBEI-18669 This study 
C3-nontarget JBEI-14034 + JBEI-18667 This study 
C4-nontarget JBEI-14034 + JBEI-18692 This study 
C5-nontarget JBEI-14034 + JBEI-18689 This study 
C6-nontarget JBEI-14034 + JBEI-18697 This study 
C7-nontarget JBEI-14034 + JBEI-18706 This study 
C8-nontarget JBEI-14034 + JBEI-18707 This study 
C5P JBEI-18698 + JBEI-18650 This study 
C5RFPNT JBEI-18698 + JBEI-18651 This study 
C5GFPNT JBEI-18698 + JBEI-18649 This study 
C6P JBEI-18698 + JBEI-18671 This study 
C6RFPNT JBEI-18698 + JBEI-18672 This study 
C6GFPNT JBEI-18698 + JBEI-18673 This study 
C5-poxB DH1, JBEI-18684 This study 
C5-ackA DH1, JBEI-18681 This study 
C5-pta DH1, JBEI-18663 This study 
C5-poxB-ackA-pta DH1, JBEI-18686 This study 
C6-poxB DH1, JBEI-18704 This study 
C6-ackA DH1, JBEI-18705 This study 
C6-pta DH1, JBEI-18702 This study 
C6-poxB-ackA-pta DH1, JBEI-18703 This study 
DH1-empty DH1, JBEI-3279 This study 
ΔpoxBΔackAΔpta JBEI-3606 This study 
DH1-knockout JBEI-3606 + JBEI-3279 This study 
KG1R10 JBEI-15391 36 
Base strain JBEI-15391 + JBEI-3279 This study 
C5-arcC JBEI-15391 + JBEI-18687 This study 
C5-yahI JBEI-15391 + JBEI-18660 This study 
C5-yqeA JBEI-15391 + JBEI-18700 This study 
C5-gltA JBEI-15391 + JBEI-18690 This study 
C5-accA JBEI-15391 + JBEI-18683 This study 
C5-eutD JBEI-15391 + JBEI-18668 This study 
C5-deoB JBEI-15391 + JBEI-18675 This study 
C5-ppc JBEI-15391 + JBEI-18678 This study 
C5-yhfW JBEI-15391 + JBEI-18701 This study 
C5-thrC JBEI-15391 + JBEI-18659 This study 
C5-ispA JBEI-15391 + JBEI-18693 This study 
C5-mdh JBEI-15391 + JBEI-18680 This study 
C5-asnA JBEI-15391 + JBEI-18685 This study 
C5-prpE JBEI-15391 + JBEI-18677 This study 
C5-gldA JBEI-15391 + JBEI-18666 This study 
C5-mqo JBEI-15391 + JBEI-18682 This study 
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C5-maeB JBEI-15391 + JBEI-18695 This study 
C5-dacA JBEI-15391 + JBEI-18694 This study 
C5-asnA-gldA JBEI-15391 + JBEI-18691 This study 
C5-asnA-prpE JBEI-15391 + JBEI-18696 This study 
C5-gldA-prpE JBEI-15391 + JBEI-18656 This study 
C5-asnA-gldA-prpE JBEI-15391 + JBEI-18688 This study 
 
 
 
